Read

Members
Client Resources
Pharmacy + Provider Resources
Drug Recalls
Events

Who we are
Our solutions
Read, watch, listen
Pharmacy
Careers

Members
Client Resources
Pharmacy + Provider Resources
Drug Recalls
Events

Home
Read, watch, listen
Read

Explore what's trending at Prime

https://primetherapeutics.com/w/prime-therapeutics-recognizes-world-cancer-day-highlights-importance-of-innovative-oncology-care Example Link

Stories

Prime Therapeutics recognizes World Cancer Day, highlights importance of innovative oncology care

February 04, 2025

https://primetherapeutics.com/w/oncology-insights-february-2025 /oncology-insights-february-2025

Research & Publications

Oncology Insights: February 2025

February 18, 2025

https://primetherapeutics.com/w/fda-decisions-expected-march-2025 /fda-decisions-expected-march-2025

Research & Publications

FDA Decisions Expected: March 2025

February 14, 2025

https://primetherapeutics.com/w/high-cost-therapy-profile-february-2025 /high-cost-therapy-profile-february-2025

Research & Publications

High-Cost Therapy Profile: February 2025

February 13, 2025

The Latest

Categories

PA Sub-Categories

https://primetherapeutics.com/w/prime-therapeutics-glp-1-research-year-2-cost-of-care-is-4-200-higher-for-patients-with-obesity

Prime Therapeutics GLP-1 research: Year-2 cost of care is $4,200 higher for patients with obesity

October 24, 2024

https://primetherapeutics.com/w/medical-benefit-drug-trend-prime-therapeutics-medical-pharmacy-trend-report-goes-behind-the-numbers-2024

Medical benefit drug trend: Prime Therapeutics Medical Pharmacy Trend Report™ goes behind the numbers

October 15, 2024

https://primetherapeutics.com/w/prime-therapeutics-bolsters-its-position-as-industry-leader-with-10-research-studies-at-amcp-nexus-2024

Prime Therapeutics bolsters its position as industry leader with 10 research studies at AMCP Nexus 2024

October 10, 2024

https://primetherapeutics.com/w/prime-therapeutics-announces-new-cost-effective-humira-biosimilar-solutions-offering-clients-flexibility-and-choice

Prime Therapeutics announces new, cost-effective Humira® biosimilar solutions, offering clients flexibility and choice

October 07, 2024

https://primetherapeutics.com/w/prime-therapeutics-llc-earns-certification-from-the-national-committee-for-quality-assurance

Prime Therapeutics LLC earns certification from the National Committee for Quality Assurance

October 03, 2024

https://primetherapeutics.com/w/prime-therapeutics-introduces-a-bold-new-brand-and-vision-to-reimagine-pharmacy-solutions

Prime Therapeutics introduces a bold new brand and vision to reimagine pharmacy solutions

September 16, 2024

Showing 1 to 6 of 34

Categories

PA Sub-Categories

https://primetherapeutics.com/w/counterfeit-glp-1s-what-to-watch-out-for

Counterfeit GLP-1s: What to watch out for

November 18, 2024

https://primetherapeutics.com/w/amcp-nexus-in-focus-exploring-prime-s-glp-1-research-in-depth

AMCP Nexus in focus: Exploring Prime’s GLP-1 research in depth

November 04, 2024

https://primetherapeutics.com/w/taking-a-closer-look-at-prime-s-glp-1-year-2-cost-of-care-findings

Taking a closer look at Prime’s GLP-1 Year-2 cost-of-care findings

October 30, 2024

https://primetherapeutics.com/w/amcp-nexus-2024-in-focus-prime-presents-keynote-specialty-pharmaceuticals-in-development-

AMCP Nexus 2024 in focus: Prime presents keynote “Specialty Pharmaceuticals in Development”

October 28, 2024

https://primetherapeutics.com/w/amcp-nexus-2024-in-focus-identifying-a-meaningful-comparison-using-propensity-score-weighting

AMCP Nexus 2024 in focus: Identifying a meaningful comparison using propensity score weighting

October 23, 2024

https://primetherapeutics.com/w/amcp-nexus-2024-in-focus-new-study-uses-social-determinants-of-health-to-better-treat-patients-with-chronic-lung-conditions

AMCP Nexus 2024 in focus: New study uses social determinants of health to better treat patients with chronic lung conditions

October 23, 2024

Showing 1 to 6 of 48

Categories

PA Sub-Categories

https://primetherapeutics.com/w/listen-now-how-prime-therapeutics-combats-fraud-waste-and-abuse-in-health-care

LISTEN NOW: How Prime Therapeutics combats fraud, waste and abuse in health care

February 06, 2025

https://primetherapeutics.com/w/prime-therapeutics-recognizes-world-cancer-day-highlights-importance-of-innovative-oncology-care

Prime Therapeutics recognizes World Cancer Day, highlights importance of innovative oncology care

February 04, 2025

https://primetherapeutics.com/w/listen-now-what-you-need-to-know-about-rsv-prevention-this-season

LISTEN NOW: What you need to know about RSV prevention this season

January 30, 2025

https://primetherapeutics.com/w/prime-therapeutics-launches-new-publication-glp-1-pipeline-update

Prime Therapeutics launches new publication, GLP-1 Pipeline Update

December 12, 2024

https://primetherapeutics.com/w/prime-participates-in-namd-fall-2024-conference

Prime participates in NAMD fall 2024 conference

November 21, 2024

https://primetherapeutics.com/w/prime-s-latest-medicaid-analysis-shows-need-for-value-based-payment-model-for-growing-number-of-million-dollar-curative-therapies

Prime’s latest Medicaid analysis shows need for value-based payment model for growing number of million-dollar curative therapies

November 19, 2024

Showing 1 to 6 of 96

Categories

PA Sub-Categories

https://primetherapeutics.com/w/prime-presents-at-isg-digital-business-summit-on-nov-14

Prime presents at ISG Digital Business Summit on Nov. 14

November 05, 2024

https://primetherapeutics.com/w/prime-presents-2024-medical-pharmacy-trend-report-webinar

Prime presents 2024 Medical Pharmacy Trend Report webinar on Oct. 24

October 01, 2024

https://primetherapeutics.com/w/prime-presents-at-amcp-nexus-2024

Prime presents at AMCP Nexus 2024 on Oct. 14–17

September 30, 2024

https://primetherapeutics.com/w/prime-presents-at-medicaid-drug-rebate-program-mdrp-summit-2024-on-sept-23-25

Prime presents at Medicaid Drug Rebate Program (MDRP) Summit 2024 on Sept. 23–25

September 23, 2024

https://primetherapeutics.com/w/prime-presents-at-72nd-annual-roy-a-bowers-conference

Prime presents at 72nd Annual Roy A. Bowers Conference on Oct. 22

September 16, 2024

https://primetherapeutics.com/w/prime-presents-at-glp-1-agonists-food-is-medicine-a-new-recipe-for-success-in-treating-obesity-a-briefing-for-congress-

Prime presents at: GLP-1 Agonists + Food is Medicine: A New Recipe for Success in Treating Obesity? A Briefing for Congress on Sept. 11

September 11, 2024

Showing 1 to 6 of 33

Categories

PA Sub-Categories

https://primetherapeutics.com/w/cancer-drugs-move-from-iv-to-sc-predictions-for-2025 https://www.managedhealthcareexecutive.com/view/cancer-drugs-move-from-iv-to-sc-predictions-for-2025

Cancer Drugs Move from IV to SC | Predictions for 2025

January 14, 2025

https://primetherapeutics.com/w/glp-1-drugs-for-weight-loss-aren-t-cost-saving-yet https://www.forbes.com/sites/joshuacohen/2025/01/02/glp-1-drugs-for-weight-loss-arent-cost-saving-yet/

GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet

January 02, 2025

https://primetherapeutics.com/w/-1-million-health-plan-savings-for-hemophilia-gene-therapy-projected https://www.specialtypharmacycontinuum.com/Clinical/Article/12-24/Gene-Therapy-Cost-Savings/75552

$1 Million Health Plan Savings for Hemophilia Gene Therapy Projected

December 13, 2024

https://primetherapeutics.com/w/prime-report-oncology-medical-benefit-drugs-continue-to-drive-trend

Prime Report: Oncology Medical Benefit Drugs Continue to Drive Trend

November 18, 2024

https://primetherapeutics.com/w/weight-loss-drugs-didn-t-curb-health-costs-within-two-years https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-drugs-didnt-curb-health-costs-within-two-years-data-show-2024-10-24/

Weight-loss drugs didn't curb health costs within two years

October 24, 2024

https://primetherapeutics.com/w/weight-loss-drugs-are-supposed-to-be-forever-until-they-run-out- https://www.washingtonpost.com/health/2024/09/24/weight-loss-drugs-wegovy-ozempic-short-supply/

Weight-loss drugs are supposed to be forever. Until they run out.

September 26, 2024

Showing 1 to 6 of 90

Categories

PA Research & Publications

https://primetherapeutics.com/w/oncology-insights-february-2025 /oncology-insights-february-2025

Oncology Insights: February 2025

February 18, 2025

https://primetherapeutics.com/w/fda-decisions-expected-march-2025 /fda-decisions-expected-march-2025

FDA Decisions Expected: March 2025

February 14, 2025

https://primetherapeutics.com/w/high-cost-therapy-profile-february-2025 /high-cost-therapy-profile-february-2025

High-Cost Therapy Profile: February 2025

February 13, 2025

https://primetherapeutics.com/w/drug-approvals-january-2025 /drug-approvals-january-2025

Drug Approvals: January 2025

January 31, 2025

https://primetherapeutics.com/w/quarterly-drug-approvals-january-2025 /quarterly-drug-approvals-january-2025

Quarterly Drug Approvals: January 2025

January 31, 2025

https://primetherapeutics.com/w/clinical-highlights-january-2025 /clinical-highlights-january-2025

Clinical Highlights: January 2025

January 30, 2025

Showing 1 to 6 of 127

Login Portals

Members and Consumers
Clients and Health Plans
Pharmacy + Provider Resources

Compliance / Legal

Privacy Policy
Notice of Privacy Practices
Terms of Use
Nondiscrimination + Languages
Subrogation

Careers

Careers Overview

Read - Prime Therapeutics

About us

Corporate social responsibility

Solutions overview

Modern technology

Drug access

Clinical solutions

Condition management

Specialty drug management

Government solutions

Single-state programs

Watch

Listen

Home Delivery

Specialty Pharmacy

Navigate to

Back

Back

Back

Back

Explore what's trending at Prime

Prime Therapeutics recognizes World Cancer Day, highlights importance of innovative oncology care

Oncology Insights: February 2025

FDA Decisions Expected: March 2025

High-Cost Therapy Profile: February 2025

The Latest

Prime Therapeutics GLP-1 research: Year-2 cost of care is $4,200 higher for patients with obesity

Medical benefit drug trend: Prime Therapeutics Medical Pharmacy Trend Report™ goes behind the numbers

Prime Therapeutics bolsters its position as industry leader with 10 research studies at AMCP Nexus 2024

Prime Therapeutics announces new, cost-effective Humira® biosimilar solutions, offering clients flexibility and choice

Prime Therapeutics LLC earns certification from the National Committee for Quality Assurance

Prime Therapeutics introduces a bold new brand and vision to reimagine pharmacy solutions

Counterfeit GLP-1s: What to watch out for

AMCP Nexus in focus: Exploring Prime’s GLP-1 research in depth

Taking a closer look at Prime’s GLP-1 Year-2 cost-of-care findings

AMCP Nexus 2024 in focus: Prime presents keynote “Specialty Pharmaceuticals in Development”

AMCP Nexus 2024 in focus: Identifying a meaningful comparison using propensity score weighting

AMCP Nexus 2024 in focus: New study uses social determinants of health to better treat patients with chronic lung conditions

LISTEN NOW: How Prime Therapeutics combats fraud, waste and abuse in health care

Prime Therapeutics recognizes World Cancer Day, highlights importance of innovative oncology care

LISTEN NOW: What you need to know about RSV prevention this season

Prime Therapeutics launches new publication, GLP-1 Pipeline Update

Prime participates in NAMD fall 2024 conference

Prime’s latest Medicaid analysis shows need for value-based payment model for growing number of million-dollar curative therapies

Prime presents at ISG Digital Business Summit on Nov. 14

Prime presents 2024 Medical Pharmacy Trend Report webinar on Oct. 24

Prime presents at AMCP Nexus 2024 on Oct. 14–17

Prime presents at Medicaid Drug Rebate Program (MDRP) Summit 2024 on Sept. 23–25

Prime presents at 72nd Annual Roy A. Bowers Conference on Oct. 22

Prime presents at: GLP-1 Agonists + Food is Medicine: A New Recipe for Success in Treating Obesity? A Briefing for Congress on Sept. 11

Cancer Drugs Move from IV to SC | Predictions for 2025

GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet

$1 Million Health Plan Savings for Hemophilia Gene Therapy Projected

Prime Report: Oncology Medical Benefit Drugs Continue to Drive Trend

Weight-loss drugs didn't curb health costs within two years

Weight-loss drugs are supposed to be forever. Until they run out.

Oncology Insights: February 2025

FDA Decisions Expected: March 2025

High-Cost Therapy Profile: February 2025

Drug Approvals: January 2025

Quarterly Drug Approvals: January 2025

Clinical Highlights: January 2025

Login Portals

Compliance / Legal

Careers